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Abstract 
Background: In patients presenting with new onset heart failure (HF) of unclear etiology the 
role of coronary angiography (CA) is unclear. CA has conventionally been performed to 
differentiate underlying coronary artery disease from dilated cardiomyopathy, but it is 
associated with a risk of complications and may not detect an ischemic etiology due to 
arterial recanalization or an embolic episode. In this study, we assessed the diagnostic 
accuracy of a cardiovascular magnetic resonance (CMR) protocol incorporating late 
gadolinium and magnetic resonance coronary angiography as a non-invasive gatekeeper to 
CA in determining the etiology of HF in this subset of patients.  
Methods and Results: 120 consecutive patients underwent CMR and CA. The etiology was 
ascribed by a consensus panel who utilized the results of the CMR scans. Similarly, a 
separate consensus group ascribed an underlying etiology by using the results of CA. The 
diagnostic accuracy of both these strategies was compared against a “gold-standard” panel 
who made a definitive judgment by reviewing all clinical data. The study was powered to 
show non-inferiority between the two techniques. LGE-CMR had a sensitivity of 100%, a 
specificity of 96% and a diagnostic accuracy of 97% which was equivalent to CA (sensitivity 
of 93%, specificity of 96% and a diagnostic accuracy of 95%). Using LGE-CMR as a gatekeeper 
to CA was also found to be a cheaper diagnostic strategy in a decision tree model (£974 vs 
£1321, p=0.001). 
Conclusions: LGE-CMR is a safe, clinically effective and economical gatekeeper to CA in 
patients presenting with HF of uncertain etiology. 
 
Key Words: gadolinium, magnetic resonance imaging, heart diseases, cardiomyopathy 
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Introduction 
Heart failure (HF) is a common disorder associated with a significant morbidity, mortality 
and financial burden to healthcare services. The most common underlying cause is coronary 
artery disease (CAD), accounting for over half of all cases, followed by non-ischemic dilated 
cardiomyopathy (DCM).1 Identification of the etiology is important as management of the 
underlying condition differs; treatment of CAD may require revascularisation and secondary 
prevention measures such as aspirin and statins, whereas pharmacotherapy remains the 
mainstay of treatment in DCM. In addition, an etiology of CAD portends a worse prognosis.2 
Accordingly, current guidelines recommend a thorough clinical assessment utilising a careful 
history, physical examination coupled with laboratory investigations, electrocardiography 
and echocardiography to try and ascertain the underlying cause and severity of HF.3 The 
same guidelines recommend invasive x-ray coronary angiography (CA) in any patients 
presenting with chest pain or significant ischemia unless the patient is not eligible for 
revascularization of any kind.  
 
The situation is less clear in those patients who do not present with chest pain and in whom 
coronary artery disease has not been excluded by means of CA. In patients with diabetes 
mellitus where ischemia may be silent or in young patients who may have coronary 
anomalies, CA may be justifiable. However, in older patients with HF but no angina there is 
no data to suggest that revascularization would improve clinical outcome.4 Any 
revascularization performed would be in the hope of improved symptoms as a result of 
augmented ventricular function. Whilst generally safe and providing hemodynamic data in 
addition to coronary imaging, the invasive nature of CA carries an inherent morbidity and  
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mortality risk.5 There are also issues of radiation burden, patient discomfort and significant 
cost. Whilst angiography is often regarded as the gold-standard, what is also now clear is 
that this investigation alone may not be sufficient to make the correct diagnosis as several 
transplant and post-mortem studies have shown that CA can misdiagnose the etiology of 
HF.6, 7  
 
We have previously demonstrated that late gadolinium enhanced cardiovascular magnetic 
resonance (LGE-CMR) may have a role in excluding coronary artery disease as the underlying 
cause of HF. The pattern of late enhancement seen on LGE-CMR differs in patients with HF 
due to DCM and CAD. A subendocardial pattern of late enhancement is seen in patients with 
CAD whereas the majority of patients with DCM have either no late enhancement or a 
patchy midwall pattern that is not related to the territory of a coronary artery.8 In addition, 
other groups have provided data to suggest that magnetic resonance coronary angiography 
(MRCA) can robustly exclude disease of either the left main coronary artery or proximal 
three-vessel disease with 100% sensitivity and 100% negative predictive value.9 We 
therefore hypothesized that in patients presenting with recent onset HF of uncertain 
etiology with no obvious ischemic basis, LGE-CMR was a non-invasive, safe and cost-
effective alternative to CA and could therefore act as a gatekeeper. 
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Methods 
Patient Population 
Patients with recently-diagnosed HF (symptom onset < 6 months prior to enrollment, 
n=124) were prospectively recruited between July 2004 and August 2006 from consecutive 
referrals seen at 6 HF clinics in south-east England. All patients had a diagnosis of HF with 
reduced LVEF based on standard criteria 3, 10 All patients were clinically stable in NYHA I-III  
HF and were aged 35 or older and were scheduled to undergo CA as part of their clinical 
work-up for HF. Exclusion criteria for the study included any prior history, ECG or 
biochemical evidence of CAD. Patients with chest pain or significant valvular disease were 
also not enrolled. In addition, as the scanning protocol involved MRCA, patients with atrial 
fibrillation were also excluded as the MRCA sequences utilized perform poorly in the context 
of a highly variable R-R interval. Finally, all patients with standard contraindications to CMR 
were also excluded. The recruited patients therefore had HF of uncertain etiology with no 
clinical evidence of CAD and were in sinus rhythm. 
 
On recruitment, patients underwent CMR with both myocardial LGE and MRCA. Patients 
also underwent CA as part of their standard clinical investigation. All patients were recruited 
prior to undergoing CA and none were denied a CMR scan as a consequence of the CA 
findings in cases where CA was performed prior to LGE-CMR. The project was approved by 
the local institutional Ethics committee. All participants gave written informed consent. 
 
Cardiovascular Magnetic Resonance 
Cine CMR (Siemens Sonata 1.5T [n=42] and Siemens Avanto [n=78]) was performed using 
steady-state, free precession breath-hold cines (TE [Echo time]/TR [Repetition time]  
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1.6/3.2ms, flip angle 60°) in long-axis planes and sequential contiguous 7mm short-axis 
slices (3mm gap) from the atrioventricular ring to the apex. LGE images were acquired 10 
minutes after intravenous gadolinium-DTPA (Schering; 0.1 mmol/kg) in identical short-axis 
(SA) planes using an inversion-recovery gradient echo sequence. Inversion times were 
adjusted to null normal myocardium (typically 320 to 440 ms; pixel size 1.7 x 1.4mm). In all 
patients, imaging was repeated for each SA image in 2 separate phase encoding directions 
to exclude artifact. LGE was only deemed to be present, when the area of signal 
enhancement could be seen in both phase-swapped images and in a cross-cut long axis 
image.  
MRCA was performed in all patients. We used using a free-breathing navigator based fat-
suppressed balanced steady state free precession sequence (SSFP) (TE = 1.47ms, TR = 
3.5ms). Phase ordering with automatic window selection (PAWS)11 was implemented to 
maximize the respiratory efficiency. For the left main (LMS), left anterior descending (LAD), 
and left circumflex coronary arteries (LCx), a 3-dimensional volume was imaged using a 
three-point planscan tool with the centre of the volume focussed on the left main coronary 
artery. Changes in the antero-posterior and left-right angulation by 5 degrees were made to 
ensure maximal coverage of the proximal LAD and LCx. The right coronary artery (RCA) was 
similarly imaged with the aid of the three-point planscan tool. Each volume consisted of 8 x 
3mm slices, reconstructed to 16 x 1.5mm slices. A field of view of 300mm x 300mm with a 
320 x 320 matrix yielded an in-plane pixel size of 0.9mm x 0.9mm. A partial Fourier factor of 
6/8 was implemented in the in-plane phase encoding direction and 25% over-sampling was 
performed in the through-plane phase encoding direction. Imaging was performed during 
the mid-diastolic rest period, the duration and onset of which were determined from  
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viewing a four-chamber cine acquisition.12 The number of phase encode steps acquired per 
cardiac cycle was dependent on the duration of this rest period and varied from 20 – 40, 
resulting in an acquisition window of 70 – 140ms and an acquisition duration ranging from 
60 – 120 cardiac cycles (assuming 100% respiratory efficiency). 
 
CMR image analysis 
Ventricular volumes and function were measured for the left ventricle using standard 
techniques,13 and analyzed using semi-automated software (CMRtools, Cardiovascular 
Imaging Solutions, London, UK). The presence of late enhancement was predefined as 
regions with an increase in signal intensity of greater than 2SD of remote normal 
myocardium. Coronary stenosis on MR angiography was predefined as >50% in any of the 
major epicardial vessels.  
 
Assessment of Etiology 
This was assessed by three independent consensus groups: 1) A CMR arm; 2) A conventional 
X-ray angiogram arm; and 3) A ‘gold-standard’ group had access to and reviewed all clinical 
and imaging data. 
 
CMR Arm: For analysis of the CMR scans for etiology of HF, a consensus group of 3 expert 
cardiologists reviewed the CMR scans using a pre-defined algorithm (figure 1). The CMR 
consensus group was presented with the patient’s clinical history including risk factors for 
coronary artery disease. They were blinded to the X-Ray angiography data. All data were 
anonymized. The cine and LGE sequences were presented. Cine imaging was carefully  
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analyzed for regional and global hypokinesia and correlated with late gadolinium images. If 
subendocardial LGE was present, the cardiologists were directed to recommend proceeding 
to CA with the view that there was evidence of underlying CAD due to evidence for prior 
myocardial infarction. In the absence of subendocardial LGE (ie either no LGE, or presence 
of midwall LGE), the MRCA images were reviewed. If the MRCA images revealed LMS or 
severe proximal 3 vessel disease, the Cardiologists were also directed to recommend 
proceeding to CA to definitively exclude CAD as the underlying etiology. In the absence of 
both subendocardial LGE and LMS/proximal 3 vessel disease on MRCA, a diagnosis of DCM 
was ascribed by the consensus panel with the implication that CA was not required for 
further evaluation of the underlying etiology. 
 
Conventional X-Ray Angiography Arm: A separate consensus group of 3 experienced 
cardiologists with expertise in coronary intervention was presented with the clinical history 
and the CA images (including left ventriculograms) in an anonymized format. These 
physicians were blinded to the CMR data, and all data were anonymized. The cardiologists 
were asked to independently ascribe an underlying etiology for the HF using a structure 
based on a standardized definition of ischemic cardiomyopathy as proposed by Felker et 
al.14 To summarize, patients were ascribed an underlying etiology of CAD if there was 
obstructive coronary artery disease of >50% in the left-main vessel, or of >75% stenosis in i) 
either the proximal LAD or ii) > 2 epicardial coronary arteries. Single vessel disease not 
involving the proximal LAD was treated as non-ischemic as the extent of LV dysfunction 
would be considered to be out of proportion to the extent of CAD. 
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Standardized coronary anatomy was used to delineate the distribution of coronary artery 
disease.15 The 3rd consensus group member’s view was only required in cases where there 
was disagreement between the 2 primary group members.  
 
Gold-standard Arm: A final independent and separate consensus group of 3 Cardiologists 
reviewed all the anonymized data and ascribed a “gold-standard” etiology based on review 
of all the clinical data including tissue characterization information from LGE-CMR as well as 
luminographic data from CA. Based on the permutations of CAD and LGE pattern seen, the 
gold-standard group categorized etiologies into 1 of 6 groups as follows: (see figure 2) 
 
1. Non-ischemic DCM: Either no LGE or midwall LGE on CMR and unobstructed 
coronary arteries on CA. (True DCM) 
2. Heart failure secondary to CAD: Ischemic pattern of LGE that involves the 
subendocardium in 3 or more segments with at least one stenosis of >75% seen in 
coronary artery(ies)16 subtending the affected area of infarction evident on CA. (True 
CAD). 
3. Non-ischemic DCM with bystander infarct: Small area of subendocardial LGE 
affecting <2 of 17 segments in a globally hypokinetic LV with unobstructed coronary 
arteries on CA. (DCM with bystander infarct).  
4. Non-ischemic DCM with bystander CAD: Either no LGE, or midwall LGE with coronary 
stenosis(es) considered insufficient to explain the extent of LV dysfunction. (DCM 
with bystander CAD ie disease not affecting the left main stem/proximal LAD or 
significant > 2 vessel disease). 
 
Assomull et al - LGE-CMR as gatekeeper to CA in HF 
10 
 
 
5. Heart failure due to ischemic heart disease with unobstructed coronary arteries: 3 or 
more segments of subendocardial/transmural LGE in a perfusion territory typical of a 
coronary artery with associated regional hypokinesia and unobstructed coronary 
arteries on CA ie probable recannalization, spasm or embolic episode. (Myocardial 
infarction with unobstructed coronary arteries). 
6. Heart failure due to CAD with no subendocardial LGE but severe proximal 3 vessel 
disease/LMS disease on CA. (Severe proximal CAD on CA without infarction) 
 
Follow-Up of Patients 
As an additional check, to corroborate the findings of the gold-standard consensus group, 
follow up data were collected prospectively in all recruited patients. Patient events were 
recorded by communication with patients, their cardiologists and general practitioners. 
Medical records were reviewed following attendance at outpatient clinics or hospitalization.  
 
All patients were directly contacted at enrolment and at 6 monthly intervals during follow 
up. No patient was lost to follow up. The data was reviewed to determine if there was any 
change in subsequent clinical diagnosis when compared to the initial diagnosis ascribed by 
the gold-standard consensus group. 
 
Diagnostic Cost Comparison 
A decision tree model was constructed with LGE-CMR positioned as a gatekeeper to CA (see 
figure 3). Using the latest cost data from the 2008-2009 United Kingdom National Health 
Service tariffs, the cost of a coronary angiogram without complications is set at £1,255.17 As 
no national NHS tariff for CMR had yet been set at the time of this study, the cost of a CMR  
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scan was set at £600 in line with current charges in UK NHS centres. The cost of using LGE-
CMR as a gatekeeper to coronary angiography was compared to using traditional method of 
utilizing only coronary angiography by implementing the above costs. The accuracy of each 
test was factored into the cost comparison by indexing the total cost of each strategy over 
the number of correct diagnoses.  
 
Statistical Analysis 
Prior to enrolment, a sample size calculation was performed in order to power the study to 
demonstrate  equivalence between LGE-CMR and CA in diagnosing the underlying etiology 
of HF.18 The sample size for this study was calculated assuming that x-ray coronary 
angiography correctly classifies the etiology on 90% of occasions and this value is the same 
for LGE-CMR. The study was powered at 80% with an alpha error of 0.05 to classify 
equivalence as a difference of less than 10% between the two diagnostic strategies. With 
these assumptions, 111 patients in each group were required and the protocol aimed for 
recruitment of 122 patients assuming a 10% drop out rate. All patients were recruited to 
both LGE-CMR and CA groups. Each consensus group was blinded to either LGE-CMR or CA 
data as appropriate thereby validating the inclusion of the same patients in both groups.  
 
All continuous variables are expressed as mean +/- SD, and the distribution of categorical 
variables is expressed as frequencies. To evaluate the relative accuracy of LGE-CMR and CA 
in diagnosing the underlying etiology of HF, calculations of sensitivity, specificity, positive  
predictive and negative predictive values (PPV and NPV) were performed with the gold 
standard consensus group diagnosis being the comparator. Comparison of the costs for the 
2 diagnostic strategies was compared using the Mann-Whitney U statistic which was  
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corrected for ties. For all statistical tests used, a p value of <0.05 was deemed to be 
statistically significant. Stata v10 was used for all statistical analyses. 
 
 
Assomull et al - LGE-CMR as gatekeeper to CA in HF 
13 
 
 
Results 
Baseline Characteristics 
The baseline characteristics of the patients are summarized in table 1. Of the 124 patients 
recruited, 4 patients did not complete the study: 2 patients were unable to tolerate LGE-
CMR scanning due to claustrophobia; 1 patient was found to have moderate to severe aortic  
regurgitation by CMR, which had not been identified by echocardiography, and 
subsequently had aortic valve surgery; 1 patient declined CA after undergoing a LGE-CMR 
and was therefore excluded. The final cohort therefore comprised of 120 patients in whom 
full LGE-CMR with MRCA was carried out without complications. The same patients also 
underwent CA, with 2 patients suffering complications requiring hospitalization (1 femoral 
artery hematoma ; 1 small occipital infarct periprocedurally). LGE-CMR was performed prior 
to CA in 81 out of 120 (68%) cases. Overall, 13 (11%) patients were admitted with acutely 
decompensated heart-failure as their index presentation. These patients were treated with 
routine anti-failure therapy and recruited to the study after stabilization and with a median 
interval of 43 days (range 4-115 days) between presentation and their CMR scan. The NYHA 
status in table 1 reflects the functional class at the time of the scan rather than the time of 
index clinical presentation. Patients had been started on conventional anti-failure therapy prior 
to undergoing their scan. In keeping with guidelines, a large proportion of patients were on 
treatment with angiotensin converting enzyme inhibitors, angiotensin receptor blockers and 
beta blockers.19 
 
Interobserver Agreement in Consensus Groups 
In the CMR consensus group, the diagnosis was unanimous in a large majority of cases, and 
a majority decision was only required in 6 (5%) cases. In the CA consensus group, the  
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diagnosis was unanimous in a large majority of cases, and a majority decision was only 
needed in 3 (2.5%) cases. Finally, in the “gold-standard” consensus group, a majority 
decision was needed in only 1 case. 
 
Diagnostic Accuracy  
After review of all clinical, LGE-CMR and CA data, the gold-standard consensus group 
deemed that 91 of the 120 cases had an underlying non-ischemic etiology and were 
therefore classified as DCM. The remaining 29 cases were deemed to represent HF 
secondary to CAD. Table 2 summarizes the breakdown of cases into subgroups as outlined in 
the methods section. 
The decision tree (figure 3) presents the diagnostic findings of LGE-CMR and CA respectively 
as well as the number of correct and incorrect diagnoses. In summary, 87 of 91 (96%) cases 
of DCM were correctly diagnosed by LGE-CMR. In the decision tree model, these 87 patients 
would theoretically be able to avoid undergoing CA thereby avoiding its associated risks as 
well as providing a significant cost saving in the diagnostic cascade. Four patients with an 
eventual diagnosis of DCM were put forward for CA in view of a limited area of bystander 
infarct. In 4 cases, LGE-CMR showed no evidence of prior infarction and hence CA was not 
indicated. However, in 2 of these cases CA documented obstructive disease in the mid LAD 
and in 2 other cases, mid vessel obstructive lesions were seen in the Cx and RCA 
respectively. All cases had severe global hypokinesia and severe LV dysfunction with no 
evidence of prior infarction on CMR and for this reason the gold standard group ascribed a 
diagnosis of DCM with “bystander” CAD.  
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LGE-CMR correctly identified all 29 patients who were ascribed CAD as the underlying 
etiology. In 2 of these cases, an etiology of CAD was ascribed despite unobstructed coronary 
arteries. This view was reached by virtue of the observation that there was a large territory 
of subendocardial/transmural LGE consistent with the supply of at least 1 major epicardial 
artery with relatively well preserved wall thickening in other unaffected areas. There were  
no cases where LGE-CMR suggested a diagnosis of DCM and corresponding CA documented 
significant LMS, proximal LAD or 3 vessel disease. Of patients with a diagnosis of DCM, 25 
had a midwall pattern of fibrosis. 
 
CA also correctly identified 87 of 91 cases (96%) of DCM. As stated above, four patients 
were incorrectly ascribed as having CAD when the gold standard diagnosis was DCM. CA 
identified all but 2 cases of HF due to CAD.  
 
The sensitivity, specificities, positive/negative predictive values and overall diagnostic 
accuracy for both LGE-CMR and CA are presented in table 3. 
 
Cost Savings of Using LGE-CMR as a Gatekeeper 
Assuming the costs for each investigation as stated in the methods section, applying the 
results from this study, the cost of using the conventional approach of CA to evaluate 
underlying etiology would be £1255 per patient. As CA has a diagnostic accuracy of 95%, the 
cost per correct diagnosis would be approximately £1321.  
 
If LGE-CMR was used as a gatekeeper, all 120 patients would undergo LGE-CMR at a cost of 
£600 per scan. However, 87 patients would subsequently be spared CA representing a net  
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saving of approximately £655 per patient. Conversely, 33 patients would undergo both LGE-
CMR and CA thereby costing £1855 per patient. Using these figures, the net cost per patient 
using LGE-CMR as a gatekeeper to CA would be significantly cheaper at £945 per patient 
(p=0.001). As LGE-CMR has a diagnostic accuracy of 97%, the cost per correct diagnosis 
would be approximately £974, which represents a 26% cost saving on using coronary 
angiography alone. 
 
Clinical follow up of recruited patients 
Follow up data were obtained for all 120 recruited patients with a mean follow up duration 
of 44.3 +/- 11.5 months. In the 87 patients in whom DCM was diagnosed on the basis of 
unobstructed coronary arteries and no subendocardial late enhancement on CMR (true 
DCM), the diagnosis did not change during the follow up period. In addition, the diagnosis in 
the 27 patients with LV dysfunction secondary to CAD as identified by both subendocardial  
scarring on CMR and significant coronary stenoses on CA (true CAD) did not change during 
follow up.  
 
In 10 cases, the findings of LGE-CMR and CA were at odds and the eventual “correct” 
diagnosis was formed by the gold-standard consensus group who reviewed all the clinical 
data. In the 4 cases of DCM with bystander CAD, only 1 patient underwent urgent 
revascularization 2 years after enrollment following an admission with NSTEMI. This patient 
was not revascularized following initial angiography as the clinician had felt the diagnosis to 
be DCM. In the other 3 cases, the patients had not presented subsequently with typical 
ischemic symptoms and their respective clinicians had treated the patients as DCM with 
pharmacotherapy and device therapy as appropriate.  
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In the 4 cases with DCM and bystander infarction, the clinicians continued treatment with a 
working diagnosis of DCM. Two of these patients also received a statin. Finally, in 2 cases 
where the diagnosis was one of prior myocardial infarction with unobstructed coronary 
arteries, both patients were treated with antifailure therapy as well as aspirin and a statin. 
One of these patients received an ICD as he had subsequently presented with sustained 
ventricular tachycardia.  
 
Discussion 
The main finding of this study is that LGE-CMR appears to be highly effective in detecting 
the basis of cardiac dysfunction in patients with newly-diagnosed HF in whom the etiology is 
unclear. It is clinically effective and economically viable as a gatekeeper to CA.  
 
Specifically, these patients have neither prior history of ischemic heart disease nor any chest 
pain that may represent underlying CAD. Current guidelines for the management of HF state 
that there is little evidence for benefit from revascularization in these groups but offers no 
firm guidance on a non-invasive alternative. This is also particularly important as nearly half 
of patients with HF and low EF have normal or near normal coronary arteries on 
angiography with an underlying myocardial disorder responsible for the clinical 
presentation. At present this is not fully characterized unless an endomyocardial biopsy is 
performed. 
 
Identification of the condition responsible for the cardiac structural and/or functional 
abnormalities may be important, as some conditions that lead to LV dysfunction are 
potentially treatable and/or reversible.3 Conventional imaging often has a low yield in  
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detecting the underlying cause and as a consequence present guidelines do not advocate 
routine angiography. This is however at odds with the practice of many healthcare providers 
and autopsy data on the underlying etiology. A major strength of CMR is its ability to 
provide tissue characterization in-vivo yielding information on the underlying etiology and 
risk stratification plus guiding device implantation.19-21 Importantly, this information is 
incremental to coronary anatomy findings alone. There is therefore an opportunity to 
reappraise the role of non-invasive imaging in identifying the underlying cause and 
management plan in this cohort of patients.  
 
Clinical Implications 
The cohort studied was representative of those normally encountered in a heart failure 
service. Most were in at least NYHA III at the time of their original index presentation. They 
had been stabilized on antifailure therapy reflected by an improvement in functional status 
by the time of recruitment; the clinical challenge was to elucidate the underlying etiology. 
 
Our data demonstrates that LGE-CMR shows diagnostic equivalence to CA in revealing the 
underlying etiology of this poorly studied cohort. In addition, the positioning of LGE-CMR as 
a gatekeeper to CA allows for the safe avoidance of CA in approximately 75% of this cohort 
who had DCM. This represents an opportunity to allow a significant cost saving in the 
management of these patients in a non-invasive manner with no ionizing radiation exposure 
or need for in-patient stay. Other advantages are that within a single test, data is provided 
on biventricular function, tissue characterization, viability as well as risk stratification.19  
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Two prior studies have quoted modest success in comparing LGE-CMR to CA in this type of 
cohort, but without additional MRCA to exclude severe proximal disease.16, 22 Both these 
studies suggest an overall sensitivity of 81-86% with a specificity of 91-93% in determining 
the presence of obstructive CAD. However, the authors acknowledged that the presence of 
obstructive CAD did not in itself represent an underlying etiology of ischemia-driven heart 
failure because of coincidental and non-contributory CAD. Indeed, in our study defining the 
gold standard for diagnosis of CAD as the contributory etiology of HF as a 70% lesion in at 
least 1 vessel would produce similar sensitivity/specificity figures to those obtained by 
Soriano et al.16 A further study23 addresses this flaw to a certain extent by using a validated 
definition for “ischemic cardiomyopathy” which allows for the presence of single vessel 
disease without a history of prior myocardial infarction to represent non-ischemic heart 
failure.14 Both studies also did not have any mechanism in their CMR protocol to detect the 
uncommon but important group of patients in whom CAD may contribute to HF by virtue of 
severe proximal 3 vessel disease without prior infarction. The use of MRCA in our study 
design addresses this potential pitfall. Our study utilized the refined, validated and more 
realistic definition for “ischemic cardiomyopathy” which precludes the scenario of a single 
lesion in either the circumflex or right coronary artery being deemed sufficient to cause 
global hypokinesia with resultant severe LV dysfunction. The present study is unique in 
being the first that is adequately powered to assess the diagnostic accuracy of LGE-CMR at 
baseline as a gatekeeper to CA when compared against a robust gold-standard. Most 
importantly, its findings are also validated against prospective clinical follow-up. 
 
The use of a “gold standard” consensus group with access to a full dataset of CMR based 
tissue characterization and coronary disease burden from CA was best equipped to provide  
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the most accurate etiology. This is because they were afforded the opportunity to integrate 
the severity of coronary disease with the extent of prior infarction and to consider whether 
the location and severity of any documented CAD would be adequate to cause ischemic 
myocardial hibernation. This study also advocates a more rigorous classification of the 
underlying etiology in patients with HF based on a combination of luminal angiography and 
myocardial tissue characterization. These have been broadly classified into 6 subsets from 
the findings of the gold-standard group and also challenges the traditional dichotomy of 
ischemic versus non-ischemic cardiomyopathy.  
 
Other smaller studies have been performed assessing LGE-CMR in a similar role with respect 
to the management of heart failure.24, 25 However, these studies included patients with 
chest pain or clinical features of CAD and therefore a comparison with our study is not 
strictly valid. Pilz et al have also used a “gatekeeper” model to argue for a role for adenosine 
stress CMR in a different cohort of patients with a class II indication for CA. Their data shows 
that the rates of CA in this cohort who have an intermediate probability of CAD could be 
reduced by over 80%.26 In our protocol, the use of first pass perfusion was considered but 
was decided against as it has been demonstrated from nuclear studies that perfusion defects 
may be present in non-ischemic cardiomyopathies.27, 28 The use of first pass perfusion would 
therefore not necessarily help in discriminating an underlying ischemic from non-ischemic 
etiology. 
 
CT coronary angiography represents a real non-invasive alternative to conventional CA.29 
However, it has a significant radiation burden and is not at present used to provide tissue 
characterization data at acceptable levels of radiation exposure. It is therefore subject to  
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the same diagnostic pitfalls as conventional CA.30, 31 There has also been interest in the role 
of stress and contrast echocardiography in a similar cohort.32 This has the advantage of 
portability and whilst it provides important information on function and ischaemia, it lacks 
detailed tissue characterization and hence cannot delineate different patterns of fibrosis. 
Interpretation is also more operator dependent. Nuclear techniques have the advantage of 
long term outcome data but also do not reliably distinguish patterns of fibrosis 
characteristic to the underlying etiology and carry a significant radiation burden.  
Increasingly, the presence of fibrosis per se has been shown to be of important prognostic 
significance and this information is not obtained by these alternative techniques. 
 
Limitations 
LGE-CMR was carried out within 37 +/-29 days of CA. Although short, this period represents 
a potential opportunity for a clinical event between the 2 procedures being performed. 
However, none of the patients had evidence of new cardiac events, required hospitalization 
or had any form of therapy changed between their respective LGE-CMR and CA. The gold-
standard diagnosis was provided by highly experienced cardiologists who were familiar with 
the performance and interpretation of CA and LGE-CMR. However, the consensus view they 
provided was effectively an opinion. This is potentially contentious in the group of patients 
who represent a “grey area” where LGE-CMR and CA provided potentially contradictory 
conclusions. However, validation of their opinion in all these “grey cases” was provided by 
3.5 year follow up data which showed that all the ascribed diagnosis by the consensus group 
was mirrored by the patients’ own physicians and clinical outcomes. In addition, the 
diagnosis only changed in 1 patient with features of DCM on LGE-CMR and single vessel CAD 
where 2 years after enrollment he re-presented with an acute coronary syndrome which  
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represented a new and unrelated event. Repeat CA in this patient demonstrated a clear 
progression of CAD which warranted revascularization with PCI. None of the patients with 
bystander CAD required or underwent revascularization with a view to evaluating any 
subsequent improvement in LV function. In addition, due to improving clinical status, none 
of the patients required or underwent myocardial biopsy. In patients, with a predominant 
DCM phenotype but with concurrent CAD, potentially, angiography provides useful 
information that could be missed by CMR alone. However, recent trials indicate that this is 
unlikely to affect outcomes in this cohort. Most notably in the CORONA trial33, statins had 
no significant benefit in patients with heart-failure, regardless of etiology. Reflecting this, 
there was no adverse outcome overall, based on their management plan. 
 
At times, the findings in this subgroup of “grey cases” may be difficult to synthesize. They 
present a diagnostic and management dilemma for clinicians and further work is therefore 
needed in uncovering the prognosis in this group compared to patients with “true DCM” (no 
CAD on CA and no subendocardial LGE on CMR). LGE-CMR does however appear to provide 
some assistance in reaching the right clinical decision in this under-recognized group. 
 
The MRCA sequence required a regular ECG to obtain images of adequate spatial resolution. 
For this reason, patients with atrial fibrillation were excluded. We also excluded all patients 
with chest pain even though this symptom may be present in heart failure of either etiology. It 
was felt that any patients with symptoms suggesting possible angina ought to have coronary 
angiography to ensure they were not denied the chance of revascularization as a therapeutic 
option.  
 
Assomull et al - LGE-CMR as gatekeeper to CA in HF 
23 
 
 
CT coronary angiography may have provided higher sensitivities and specificities in the 
exclusion of coronary artery disease but with an increased radiation burden along with the 
risks associated with iodine-based contrast agents. Detailed tissue characterisation is also not 
currently possible with CT.  MRCA was included in our protocol to ensure that we did not miss 
patients with severe proximal coronary disease but no infarction. However, no such patients 
were encountered suggesting that this is an important but uncommon presentation.24  
 
It should also be noted that the cohort we studied consisted predominantly of patients with 
mild to moderate heart failure in sinus rhythm and no symptoms consistent with myocardial 
ischemia, and may not apply to patients with more severe or advanced heart failure. This is 
also relevant to MRCA which may have a different and potentially lower negative predictive 
value in a broader cohort of heart-failure Patients where there is a higher burden of CAD. 
Finally, the potential cost-savings of this procedure will depend upon local/national relative 
reimbursement rates for both CMR and CA, and hence this data is most applicable to 
healthcare services such as the UK where CMR is less expensive than CA. 
 
Conclusions 
CMR is a safe, clinically effective and fiscally prudent gatekeeper to CA in patients 
presenting with new onset HF with no features of chest pain or prior myocardial infarction. 
It is of particular value in clarifying the underlying pathophysiology in patients who are likely 
to have dual pathology by establishing the dominant etiology. Additional information is 
provided on biventricular assessment, tissue characterization, risk stratification and 
likelihood to benefit from device therapy. Unique aspects of our study compared to 
previous work are comparison of findings with a gold-standard panel including CMR and  
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angiography rather than CA alone, and in addition, corroboration of these findings through 
subsequent clinical follow-up.  Our study also suggests the need for a paradigm shift from a 
simple classification of ischemic vs non-ischemic etiologies in this cohort, based on 
luminography, to one that refines the Felker criteria incorporating myocardial tissue  
characterization. Further studies are required to identify the prognosis in this cohort with 
particular focus on the subgroup of grey cases in whom there appears to be concurrent CAD 
with non-ischemic DCM.  
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 Figure legends 
Figure 1: Pre-defined decision algorithm for CMR consensus panel to decide whether to 
proceed to invasive x-ray coronary angiography (CA). The algorithm states that the presence 
of subendocardial late gadolinium enhancement (LGE) should trigger the decision to 
proceed to CA. In cases where, subendocardial LGE is not present, magnetic resonance 
coronary angiography (MRCA) images should be reviewed before deciding whether CA is 
required. The review of MRCA should exclude proximal severe 3 vessel disease or left main 
stem (LMS) disease before a scan be labelled as dilated cardiomyopathy (DCM). 
 
Figure 2: Late gadolinium enhanced cardiovascular magnetic resonance (LGE-CMR) and 
associated coronary angiogram (CA) images of diagnosis subtypes. Six different diagnoses 
are graphically represented with LGE-CMR images followed by CA images of the left 
coronary artery (LCA) and right coronary artery (RCA). True dilated cardiomyopathy (DCM) 
as depicted in row a) shows an LGE-CMR image with no subendocardial LGE and 
unobstructed coronary arteries on CA. In row b), true coronary artery disease (CAD) is 
depicted with a circumflex territory infarct on CMR (arrows) as well as a severe proximal 
circumflex artery stenosis (arrows). In row c) a small area of subendocardial LGE(arrows) is 
seen in a severely dilated LV with severe global systolic impairment and unobstructed 
coronary arteries representing DCM with bystander infarct. In row d) distal disease of the 
left anterior descending artery is seen (arrows) with no evidence of subendocardial LGE 
(DCM with bystander CAD). In row e) a large apical infarct is seen on LGE-CMR in the context 
of unobstructed coronary arteries suggesting ischemic heart failure (HF) with unobstructed 
coronary arteries. Finally, the images in row f) show a possible scenario of ischemic heart 
failure without infarction. There is no LGE on CMR but severe proximal 3 vessel disease  
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including left main stem disease on CA (arrows). No patient in our study had this scenario and 
therefore the images are for illustration only. 
 
Figure 3: A decision tree model summarizing the results of the decisions made by the late 
gadolinium enhanced cardiovascular magnetic resonance (LGE-CMR), coronary angiography 
(CA) and gold standard consensus panel groups. The model delineates the role of LGE-CMR 
with incorporated magnetic resonance coronary angiography (MRCA) as a gatekeeper to CA. 
In this model, 87 (73%) of the recruited cohort safely avoided CA and were correctly 
ascribed a diagnosis of DCM by LGE-CMR. The relative diagnostic performance of using LGE-
CMR against CA is represented by the true and false positive (TP/FP) as well as true and false 
negative (TN/FN) numbers presented at the end of the decision tree.   
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Table legends 
Table 1: Baseline characteristics of the study group. DCM- dilated cardiomyopathy ; CAD- 
coronary artery disease; CMR- cardiovascular magnetic resonance; NYHA – New York Heart 
Association heart failure class; ACEi – angiotensin converting enzyme inhibitor; ARB – 
angiotensin 2 receptor blocker; LV - left ventricle; EDVI – end-diastolic volume index; ESV- 
end-systolic volume index; EF- ejection fraction. 
 
Table 2: Final categorization of etiology as ascribed by Gold Standard Consensus Panel. DCM 
– dilated cardiomyopathy; CAD- coronary artery disease; CA: invasive x-ray coronary 
angiography. 
 
Table: 3: Table showing sensitivity, specificities, positive predictive values (PPV), negative 
predictive values (NPV) and diagnostic accuracy of late gadolinium-enhanced (LGE-CMR) and 
invasive x-ray coronary angiography (CA) vs the gold standard consensus group diagnosis 
(columns 2 and 3).  
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Table 1: Baseline Characteristics at time of CMR Scan 
 
Characteristic n=120 
Age (years) (SD) 57 (11) 
Male sex (%) 96 (80) 
Family history of DCM (%) 7 (6) 
Family history of CAD (%) 20 (17) 
History of diabetes (%) 20 (17) 
History of hypertension (%) 56 (47) 
History of smoking (%) 29 (24) 
History of alcohol excess (%) 7 (6) 
Preceding flu like illness (%) 11 (9) 
Heart Failure duration prior to enrollment in days (SD) 63 (39) 
Interval between CMR and Coronary Angiogram (days) (SD) 37 (29) 
NYHA Class at time of enrollment (%)  
I 29 (24) 
II 75 (63) 
III 16 (13) 
Medication (%)  
Aspirin 56 (47) 
ACEI/ARB 110 (92) 
Beta Blocker 84 (70) 
Spironolactone 24 (20) 
Digoxin 2 (2) 
Diuretics 73 (61) 
Anticoagulation 11 (9) 
Amiodarone 4 (3) 
Statins 56 (47) 
CMR Dimensions and Function (SD)  
LVEDVI (mL/m2) 130 (48) 
LVESVI (mL/m2) 84 (48) 
LVEF (%) 39 (13) 
LV MassI (g/m2) 113 (37) 
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Table 2: Gold-standard Consensus Panel Categorization list  
 
Diagnosis N (%) 
DCM: True DCM 83 (69) 
CAD: True CAD 27 (23) 
DCM: Bystander infarct 4 (3) 
DCM: Bystander CAD 4 (3) 
CAD: MI with unobstructed coronary arteries on 
CA 
2 (2) 
CAD: Severe proximal CAD on CA with no 
infarction 
0 (0) 
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Table 3: Diagnostic accuracy of LGE-CMR and CA 
 
 LGE-CMR (95% CI) CA (95% CI) 
Sensitivity % 100 (88-100) 93 (77-99) 
Specificity % 96 (89-99) 96 (89-99) 
PPV % 88 (72-97) 87 (70-96) 
NPV %  100 (96-100) 98 (92-100) 
Diagnostic accuracy % 97 95 
 
 
